2-咪唑-1-基噻吩-3-胺 | 615535-07-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-咪唑-1-基噻吩-3-胺
• 英文名称: 2-(1H-imidazol-1-yl)thiophen-3-amine
• 英文别名: 2-imidazol-1-ylthiophen-3-amine
• CAS: 615535-07-4
• 化学式: C₇H₇N₃S
• 分子量: 165.219
• InChiKey: USRFMKWNPLCINM-UHFFFAOYSA-N

物化性质

• 沸点：
  410.9±30.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-萘乙酸 、 2-咪唑-1-基噻吩-3-胺 在 吡啶 、 三氯氧磷 作用下， 生成 N-(2-(1H-imidazol-1-yl)thiophen-3-yl)-2-(naphthalen-1-yl)acetamide
  参考文献：
  名称：

  Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK

  摘要：

  From high throughput screening, we discovered compound 1, the prototype for a series of disubstituted thiophene inhibitors of JNK which is selective towards closely related MAP kinases p38 and Erk2. Herein we describe the evolution of these compounds to a novel class of thiophene and thiazole JNK inhibitors that retain favorable solubility, permeability, and P-gp properties for development as CNS agents for treatment of neurodegeneration. Compound 61 demonstrated JNK3 IC(50) = 77 nM and retained the excellent broad kinase selectivity observed for the series. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.066
• 作为产物：
  描述：

  1-(3-nitrothiophen-2-yl)-1H-imidazole 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 22.25h， 以87.6%的产率得到2-咪唑-1-基噻吩-3-胺
  参考文献：
  名称：

  [EN] THIOPENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
  [FR] COMPOSÉS TRICYCLIQUES À BASE DE THIOPÈNE ET COMPOSITIONS PHARMACEUTIQUES RENFERMANT LESDITS COMPOSÉS

  摘要：

  具有公式(I)的化合物，以及其中所述化合物的药物可接受的盐、水合物和前药，作为抗炎剂是有用的，其中R1、R2和R3是氢、卤素、烷基或全氟烷基；R4是可选地取代的烷基或环烷基团；X是连接基；A是芳基、杂芳基、杂环、环烷基，或是缺失的；R7是如说明书中定义的A上的取代基。

  公开号：

  WO2003084959A1

文献信息

• [EN] INHIBITORS OF JUN N-TERMINAL KINASE<br/>[FR] INHIBITEURS DE L'ENZYME JUN N-TERMINAL KINASE
  申请人：ELAN PHARM INC

  公开号：WO2010091310A1

  公开（公告）日：2010-08-12

  The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

  本公开提供了具有以下结构的c-Jun N-末端激酶（JNK）抑制剂（I）的结构，或其盐或溶剂化物，其中环A，Ca，Cb，Z，R5，W和Cy在此处定义。本公开还提供了包括本公开化合物的药物组合物，以及制备和使用本公开化合物和组合物的方法，例如在治疗和预防各种疾病，如阿尔茨海默病。
• Inhibitors of Jun N-terminal kinase
  申请人：Sham Hing L.

  公开号：US08450363B2

  公开（公告）日：2013-05-28

  The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

  本公开提供具有以下公式结构的c-Jun N末端激酶（JNK）抑制剂：或其盐或溶剂，其中环A、Ca、Cb、Z、R5、W和Cy在此定义。本公开还提供包括本公开化合物的药物组合物以及制备和使用本公开化合物和组合物的方法，例如，在治疗和预防各种疾病，如阿尔茨海默病方面的应用。
• INHIBITORS OF JUN N-TERMINAL KINASE
  申请人：SHAM Hing L.

  公开号：US20130072494A1

  公开（公告）日：2013-03-21

  The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, C a , C b , Z, R 5 , W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

  本公开提供了具有以下结构的c-Jun N端激酶（JNK）抑制剂： 或其盐或溶剂，其中环A、Ca、Cb、Z、R5、W和Cy在此被定义。本公开还提供了包括本公开化合物的药物组合物以及制备和使用本公开化合物和组合物的方法，例如，在治疗和预防各种疾病，如阿尔茨海默病中使用。
• Inhibitors of Jun N-Terminal Kinase
  申请人：Sham Hing L.

  公开号：US20100331335A1

  公开（公告）日：2010-12-30

  The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, C a , C b , Z, R 5 , W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

  本公开提供抑制c-Jun N-末端激酶（JNK）的抑制剂，其结构符合以下公式：其中环A、Ca、Cb、Z、R5、W和Cy在此定义。本公开还提供包括本公开化合物的药物组合物以及制备和使用本公开化合物和组合物的方法，例如在治疗和预防各种疾病，如阿尔茨海默病中的应用。
• THIOPHENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
  申请人：Bristol-Myers Squibb Company

  公开号：EP1490371B1

  公开（公告）日：2007-08-15